Longevity science projects funded by VitaDAO
VitaDAO primarily funds translational R&D. We are particularly interested in ‘moonshots’ – potential revolutionary contributions to science. On occasion we will also fund more ‘basic’ research and other projects in the interests of the LongBio community.
Explore our portfolio of funded projects, or follow the link below to submit your own project for funding.
$4.2M+
Funding Deployed
24
Research Projects Funded
200+
Projects Evaluated
$6M+
Liquid Funds
.png)
ARTAN is a biotechnology company developing first-in-class interventions to tackle the most frequent nonsense mutations implicated in a wide range of age-related diseases and cancers. These nonsense mutations induce premature stops of protein translation when occurring in coding regions.
Autophagy - the mechanism to recycle cellular components - becomes dysregulated with age and is associated with numerous diseases. The Korolchuk lab, based at Newcastle University, will screen a compound library to identify novel autophagy-activating compounds with the aim of restoring autophagy function to aged cells.
Discovering Novel Autophagy Activators - Korolchuk Lab
Autophagy - the mechanism to recycle cellular components - becomes dysregulated with age and is associated with numerous diseases. The Korolchuk lab, based at Newcastle University, will screen a compound library to identify novel autophagy-activating compounds with the aim of restoring autophagy function to aged cells.
ARTAN Bio - Mutation-Specific Codon Suppression for Aging and Longevity
ARTAN is a biotechnology company developing first-in-class interventions to tackle the most frequent nonsense mutations implicated in a wide range of age-related diseases and cancers. These nonsense mutations induce premature stops of protein translation when occurring in coding regions.
Matrix Bio - Long-lived Species Inspired Longevity Biotech
VitaDAO and the Gorbunova Lab are launching Matrix Bio, a cutting-edge research venture leveraging the anti-cancer and pro-longevity effects of high molecular weight hyaluronic acid from naked mole rats to humans.
The Longevity Molecule - Scheibye-Knudsen Lab
What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.4 billion prescriptions to understand the impact of drugs on human lifespan.
.png)
ApoptoSENS - Senolytic CAR-NK Cells
SENS Research Foundation researcher Dr. Amit Sharma has identified senescence-specific cell surface biomarkers, leading to the development of Chimeric Antigen Receptor Natural Killer (CAR-NK) cells that can eliminate senescent cells in vivo. This innovative approach holds promise for combating age-related diseases and extending lifespan.
Novel Mitophagy Activators for Alzheimer’s Disease - Fang Lab
Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age and is thought to be a driver of Alzheimer’s and other age-related diseases. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.
Reversing Periodontal Disease using Geroscience - An Lab
The greatest underlying risk factor for periodontitis is age, and its association with other age-related diseases. Jonathan An’s lab proposes to test a series of compounds targeting inflammation in a mouse model of age-related periodontitis, with the goal of finding a geroscience-based treatment for this neglected disease that has a severe impact on human healthspan.
Study on Exercise & Rapamycin - Safety and Efficacy Clinical Trial
This clinical trial aims to investigate whether periods of time where the mechanistic target of Rapamycin (mTOR) pathway is activated via exercise, combined with alternate periods of time where mTOR is inhibited using Sirolimus (Rapamycin), will result in greater muscle performance in older adults compared with just exercise alone.
Transfidelity
Project Transfidelity aims to take a new approach to treating neurodegenerative diseases by developing novel compounds that improve the accuracy of protein translation. In simple terms, we’re going to upgrade the factory’s quality control systems.
Turn Biotechnologies - mRNA Therapeutics with Lipid Nanoparticle Delivery
Turn Bio develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. They are reprogramming the epigenome – a network of chemical compounds and proteins controlling cell functions to restore capabilities that are lost with age.
Rubedo.Life - Prodrug Discovery Platform
Rubedo is building a platform for longevity medicines using “smart drugs” (prodrugs) that have the capacity to selectively be activated in target cells predicted to be pathogenic and the cause of age-related diseases.
BE Therapeutics - Brain Tissue Replacement
The neocortex, the part that underlies our highest cognitive functions and self-identity, can be replaced by progressively replacing tissue areas over time without significant disruption in function or self-identity. This offers the possibility of age reversal for the neocortex through progressive tissue replacement.
ExcepGen Inc - RNA therapeutics for longevity
ExcepGen uses its RNAx platform to develop advanced vaccines that address viral infections linked to premature aging and shortened lifespan. The platform improves RNA cargo's effectiveness, promoting significant protein production for enhanced protection.
GERO - Physics and AI Technology Platform for Age-Related Diseases
GERO uses physics and AI to develop a proprietary technology platform to understand the aging process and create a pipeline of drug candidates and therapies targeting multiple age-related chronic diseases. Their ultimate aim is to dramatically slow down aging.
Zoe Biosciences - PAI-1 Antibody Therapeutics
An early-stage therapeutic biotech with two programs - each centered on targets that are well-validated both for longevity and aging-related diseases.
Cyclarity - Novel Cyclodextrin Molecules for Multiple Aging-related Diseases
Cyclarity Therapeutics is an early stage biotechnology company developing computationally designed novel cyclodextrin drug molecules for the extraction of toxic biomolecules that accumulate with age and are implicated in a variety of age-related conditions.
Etheros - Fullerene Chemistry for Longevity
Etheros is developing a new class of small molecule drugs based on fullerene chemistry. The lead compound has shown to extend mouse lifespan, improve cognition in elderly mice, and has been neuroprotective in various animal studies. The compounds mimic enzymes that protect cells from oxidative and inflammatory injury. The current raise will help Etheros improve its IP portfolio
HDAX Therapeutics - Histone Deacetylase Targeting Drug Discovery
HDAX is a preclinical-stage drug discovery company targeting a class of proteins implicated in neuropathies and inflammation with novel small molecules.
ImmuneAge Bio - Rejuvenation of Aged HSCs
ImmuneAGE Bio is the first drug discovery platform company focused on immune system rejuvenation. ImmuneAGE rejuvenates hematopoietic stem cells (HSCs) from the bone marrow based on a geroscience screening platform enabled by a new ‘StemSupply’ method achieving >1000x expansion of HSCs.
Oisín Biotechnologies - Pioneering Genetic Medicines for Sarcopenia
Oisín Biotechnologies is a multi-asset longevity biotech company pioneering genetic medicines to combat sarcopenia and other age-related diseases to promote healthier, longer lives.
Remedium Bio - Gene Therapy for Regenerative Medicine
Remedium Bio is a regenerative medicine biotechnology company, that has developed the only dose-adjustable gene therapy platform technology Prometheus™ and is currently advancing multiple assets with uncorrelated risk to Investigational New Drug (IND) approval.
Repair Biotechnologies - First-in-class Cell Therapy for Atherosclerosis
Repair Biotechnologies is a preclinical-stage biotech company developing a first-in-class universal cell therapy for atherosclerosis. It aims to reduce the risk of cardiovascular events, such as heart attack and stroke.
Humanity - Proprietary Aging Score App
Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.
Mantis Photonics - Hyperspectral Imaging for Degenerative Disease
Mantis Photonics AB is developing a hyperspectral camera for retinal imaging for the early screening of Alzheimer's Disease via the detection of the Amyloid beta peptide. The retina displays similarities to the brain and spinal cord in terms of anatomy, functionality and response to insult, hence, the eye providing a unique window to the central nervous system.
Longevity Hackers Film Participation
A groundbreaking documentary examining the latest research and scientific breakthroughs in the field of longevity and healthy life extension. Featuring wide-ranging interviews from the researchers leading the charge to longevity critics, the film aims to educate and raise awareness, whilst providing a balanced analysis of this exciting and pioneering space.
The Longevity Prize
The Longevity Prize is a series of prizes to award and accelerate progress in longevity and rejuvenation research. It was initiated by VitaDAO and funded through donations through our gitcoin quadratic donation round and partnered with Foresight Institute, Methuselah Foundation and Lifespan.
The VitaDAO Longevity Fellowship
The VitaDAO Longevity Fellowship is aimed at distributing need-based micro grants to help students and early career stage individuals with interest in longevity get more deeply involved in longevity. This is aimed at activities ranging from short term research to attending a conference, or joining a program such as the Longevity Biotech Fellowship.
The Longevity Decentralized Review (TLDR)
The Longevity Decentralized Review (TLDR) is an on-demand service that provides peer reviews of scientific manuscripts and compensates reviewers for their work. It is funded from fees of those who submit their research to be reviewed, as well as donations. The focus of the content is longevity research posted to preprint servers such as Biorxiv, Medrxiv, and Arxiv.
The Longevist - Overlay Longevity Research Journal
An overlay journal to curate the most impactful longevity research every quarter, as voted by a mix of industry & academic experts in the longevity space.
Longevity Quadratic Funding
Committed to magnifying public good project impact, VitaDAO, among other donors, pledges substantial matching funds for curated longevity projects, leveraging crypto communities for groundbreaking research.
Zuzalu
Initiated by Vitalik Buterin, Zuzalu is a pioneering experiment in social innovation and community-driven progress. With VitaDAO's backing, Zuzalu is exploring the multiple facets of longevity science; from biotech innovation to rethinking traditional frameworks that govern medical research. Zuzalu’s first pop-up city was co-organised by VitaDAO and attended by some of the world’s most accomplished builders, futurists, and social visionaries.
The Longevity Prize
The Longevity Prize is a series of prizes to award and accelerate progress in longevity and rejuvenation research. It was initiated by VitaDAO and funded through donations through our gitcoin quadratic donation round and partnered with Foresight Institute, Methuselah Foundation and Lifespan.
The VitaDAO Longevity Fellowship
The VitaDAO Longevity Fellowship is aimed at distributing need-based micro grants to help students and early career stage individuals with interest in longevity get more deeply involved in longevity. This is aimed at activities ranging from short term research to attending a conference, or joining a program such as the Longevity Biotech Fellowship.
The Longevity Decentralized Review (TLDR)
The Longevity Decentralized Review (TLDR) is an on-demand service that provides peer reviews of scientific manuscripts and compensates reviewers for their work. It is funded from fees of those who submit their research to be reviewed, as well as donations. The focus of the content is longevity research posted to preprint servers such as Biorxiv, Medrxiv, and Arxiv.
The Longevist - Overlay Longevity Research Journal
An overlay journal to curate the most impactful longevity research every quarter, as voted by a mix of industry & academic experts in the longevity space.
